Cargando…

Levetiracetam may be an unsuitable choice for patients with PRRT2-associated self-limited infantile epilepsy

INTRODUCTION: Self-limited infantile epilepsy (SeLIE) is a benign epilepsy. Previous studies have shown that monotherapy with most antiseizure medications can effectively relieve seizures in patients with SeLIE, but the efficacy of levetiracetam has not been investigated. OBJECTIVE: This study aimed...

Descripción completa

Detalles Bibliográficos
Autores principales: Tian, Yang, Shi, Zhen, Cai, Jiahao, Hou, Chi, Wang, Xiuying, Zhu, Haixia, Peng, Binwei, Shi, Kaili, Li, Xiaojing, Gong, Sitang, Chen, Wen-Xiong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2023
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601096/
https://www.ncbi.nlm.nih.gov/pubmed/37880614
http://dx.doi.org/10.1186/s12887-023-04212-w
_version_ 1785126123592482816
author Tian, Yang
Shi, Zhen
Cai, Jiahao
Hou, Chi
Wang, Xiuying
Zhu, Haixia
Peng, Binwei
Shi, Kaili
Li, Xiaojing
Gong, Sitang
Chen, Wen-Xiong
author_facet Tian, Yang
Shi, Zhen
Cai, Jiahao
Hou, Chi
Wang, Xiuying
Zhu, Haixia
Peng, Binwei
Shi, Kaili
Li, Xiaojing
Gong, Sitang
Chen, Wen-Xiong
author_sort Tian, Yang
collection PubMed
description INTRODUCTION: Self-limited infantile epilepsy (SeLIE) is a benign epilepsy. Previous studies have shown that monotherapy with most antiseizure medications can effectively relieve seizures in patients with SeLIE, but the efficacy of levetiracetam has not been investigated. OBJECTIVE: This study aimed to investigate the efficacy of levetiracetam in the treatment of SeLIE patients with PRRT2 mutations. METHODS: The clinical data of 39 SeLIE patients (21 males and 18 females, aged 4.79 ± 1.60 months) with pathogenic variants in PRRT2 or 16p11.2 microdeletion were retrospectively analyzed. Based on the use of initial antiseizure medication (ASM), the patients were classified into two groups: Levetiracetam group (LEG) and Other ASMs group (OAG). The difference of efficacy between the two groups was compared. RESULTS: Among the 39 SeLIE patients, 16 were LEG (10 males and 6 females, aged 5.25 ± 2.07 months), with whom two obtained a seizure-free status (12.50%) and 14 ineffective or even deteriorated (87.50%). Among the 14 ineffective or deteriorated cases, 13 were seizure-controlled after replacing levetiracetam with other ASMs including topiramate, oxcarbazepine, lamotrigine, and valproate, and the remaining one finally achieved remission at age 3. Of the 39 patients, 23 were OAG (11 males and 12 females; aged 4.48 ± 1.12 months), of whom 22 achieved seizure remission, except for one patient who was ineffective with topiramate initially and relieved by oxcarbazepine instead. Although there were no significant differences in gender and age of onset between the two groups, the effective rate was significantly different (12.50% in LEG vs. 95.65% in OAG) (P < 0.01). CONCLUSION: The findings showed that patients with SeLIE caused by the PRRT2 mutations did not benefit from the use of levetiracetam, but could benefit from other ASMs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-023-04212-w.
format Online
Article
Text
id pubmed-10601096
institution National Center for Biotechnology Information
language English
publishDate 2023
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-106010962023-10-27 Levetiracetam may be an unsuitable choice for patients with PRRT2-associated self-limited infantile epilepsy Tian, Yang Shi, Zhen Cai, Jiahao Hou, Chi Wang, Xiuying Zhu, Haixia Peng, Binwei Shi, Kaili Li, Xiaojing Gong, Sitang Chen, Wen-Xiong BMC Pediatr Research INTRODUCTION: Self-limited infantile epilepsy (SeLIE) is a benign epilepsy. Previous studies have shown that monotherapy with most antiseizure medications can effectively relieve seizures in patients with SeLIE, but the efficacy of levetiracetam has not been investigated. OBJECTIVE: This study aimed to investigate the efficacy of levetiracetam in the treatment of SeLIE patients with PRRT2 mutations. METHODS: The clinical data of 39 SeLIE patients (21 males and 18 females, aged 4.79 ± 1.60 months) with pathogenic variants in PRRT2 or 16p11.2 microdeletion were retrospectively analyzed. Based on the use of initial antiseizure medication (ASM), the patients were classified into two groups: Levetiracetam group (LEG) and Other ASMs group (OAG). The difference of efficacy between the two groups was compared. RESULTS: Among the 39 SeLIE patients, 16 were LEG (10 males and 6 females, aged 5.25 ± 2.07 months), with whom two obtained a seizure-free status (12.50%) and 14 ineffective or even deteriorated (87.50%). Among the 14 ineffective or deteriorated cases, 13 were seizure-controlled after replacing levetiracetam with other ASMs including topiramate, oxcarbazepine, lamotrigine, and valproate, and the remaining one finally achieved remission at age 3. Of the 39 patients, 23 were OAG (11 males and 12 females; aged 4.48 ± 1.12 months), of whom 22 achieved seizure remission, except for one patient who was ineffective with topiramate initially and relieved by oxcarbazepine instead. Although there were no significant differences in gender and age of onset between the two groups, the effective rate was significantly different (12.50% in LEG vs. 95.65% in OAG) (P < 0.01). CONCLUSION: The findings showed that patients with SeLIE caused by the PRRT2 mutations did not benefit from the use of levetiracetam, but could benefit from other ASMs. SUPPLEMENTARY INFORMATION: The online version contains supplementary material available at 10.1186/s12887-023-04212-w. BioMed Central 2023-10-25 /pmc/articles/PMC10601096/ /pubmed/37880614 http://dx.doi.org/10.1186/s12887-023-04212-w Text en © The Author(s) 2023 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) . The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/ (https://creativecommons.org/publicdomain/zero/1.0/) ) applies to the data made available in this article, unless otherwise stated in a credit line to the data.
spellingShingle Research
Tian, Yang
Shi, Zhen
Cai, Jiahao
Hou, Chi
Wang, Xiuying
Zhu, Haixia
Peng, Binwei
Shi, Kaili
Li, Xiaojing
Gong, Sitang
Chen, Wen-Xiong
Levetiracetam may be an unsuitable choice for patients with PRRT2-associated self-limited infantile epilepsy
title Levetiracetam may be an unsuitable choice for patients with PRRT2-associated self-limited infantile epilepsy
title_full Levetiracetam may be an unsuitable choice for patients with PRRT2-associated self-limited infantile epilepsy
title_fullStr Levetiracetam may be an unsuitable choice for patients with PRRT2-associated self-limited infantile epilepsy
title_full_unstemmed Levetiracetam may be an unsuitable choice for patients with PRRT2-associated self-limited infantile epilepsy
title_short Levetiracetam may be an unsuitable choice for patients with PRRT2-associated self-limited infantile epilepsy
title_sort levetiracetam may be an unsuitable choice for patients with prrt2-associated self-limited infantile epilepsy
topic Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10601096/
https://www.ncbi.nlm.nih.gov/pubmed/37880614
http://dx.doi.org/10.1186/s12887-023-04212-w
work_keys_str_mv AT tianyang levetiracetammaybeanunsuitablechoiceforpatientswithprrt2associatedselflimitedinfantileepilepsy
AT shizhen levetiracetammaybeanunsuitablechoiceforpatientswithprrt2associatedselflimitedinfantileepilepsy
AT caijiahao levetiracetammaybeanunsuitablechoiceforpatientswithprrt2associatedselflimitedinfantileepilepsy
AT houchi levetiracetammaybeanunsuitablechoiceforpatientswithprrt2associatedselflimitedinfantileepilepsy
AT wangxiuying levetiracetammaybeanunsuitablechoiceforpatientswithprrt2associatedselflimitedinfantileepilepsy
AT zhuhaixia levetiracetammaybeanunsuitablechoiceforpatientswithprrt2associatedselflimitedinfantileepilepsy
AT pengbinwei levetiracetammaybeanunsuitablechoiceforpatientswithprrt2associatedselflimitedinfantileepilepsy
AT shikaili levetiracetammaybeanunsuitablechoiceforpatientswithprrt2associatedselflimitedinfantileepilepsy
AT lixiaojing levetiracetammaybeanunsuitablechoiceforpatientswithprrt2associatedselflimitedinfantileepilepsy
AT gongsitang levetiracetammaybeanunsuitablechoiceforpatientswithprrt2associatedselflimitedinfantileepilepsy
AT chenwenxiong levetiracetammaybeanunsuitablechoiceforpatientswithprrt2associatedselflimitedinfantileepilepsy